Related Experiment Videos
Antibiotic safety assessment
1Service de Pharmacologie Clinique, CNRS UPRES A 8068, Hôpital Cochin, 27 rue du Fbg Saint Jacques, 75679 Paris Cedex 14, France. bernard.rouveix@cch.ap-hop-paris.fr
International Journal of Antimicrobial Agents
|March 15, 2003
Summary
Severe antibiotic adverse drug reactions (ADRs) can be serious, but understanding drug structure, metabolism, and pharmacokinetics can help predict and prevent toxicity. Future genomic tools may identify at-risk patients for safer antibiotic use.
Area of Science:
- Pharmacology and Toxicology
- Drug Safety and Pharmacovigilance
- Medicinal Chemistry
Background:
- Antibiotics generally offer a favorable risk-benefit profile, with adverse effects typically mild and reversible.
- Severe adverse drug reactions (ADRs) to antibiotics, however, can lead to significant morbidity and mortality, necessitating the withdrawal of some drugs.
- The documentation of antibiotic-related ADRs is often insufficient, highlighting a need for improved investigation and prevention strategies.
Purpose of the Study:
- To review current methodologies for investigating and preventing antibiotic-induced toxicity.
- To explore potential future research directions in mitigating antibiotic ADRs.
Main Methods:
- Investigating structure-ADR relationships for various antibiotic classes (e.g., beta-lactams, macrolides, quinolones).
- Examining the role of stereochemical composition, such as enantiomers in quinolones (e.g., ofloxacin), in differential toxicity.
- Considering metabolic variability, genetic differences in drug-metabolizing enzymes, and reactive metabolites as contributors to idiosyncratic toxicity.
- Evaluating the potential of advanced molecular biology techniques, including individual genomic characterization (DNA chip technology), for risk identification.
- Utilizing pharmacokinetic parameters like area under the curve (AUC) and maximum concentration (Cmax) for predicting adverse effects.
Main Results:
- Stereochemical differences, like those between ofloxacin enantiomers, can influence antibiotic toxicity.
- Genetic variations in drug-metabolizing enzymes contribute to population-level differences in ADR risk.
- Chemically reactive metabolites can underlie idiosyncratic antibiotic toxicity.
- Pharmacokinetic parameters show potential for predicting adverse effects.
Conclusions:
- Understanding structure-ADR relationships and metabolic variability is crucial for reducing antibiotic toxicity.
- Genomic characterization holds promise for identifying patients at heightened risk of ADRs.
- Pharmacokinetic profiling can aid in predicting and managing antibiotic-related adverse events.